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The factors which cause the progression of intrinsic renal
disease to the condition of end-stage renal failure are ill defined
and poorly understood. That this is the case is exemplified by
the theories that abound purporting to explain this progression
[1, 2]. Current hypotheses are many, but among the more
credible are:
—Increased intraglomerular pressure/hypertension
—Activation of the coagulation system
—Lipid depàsition
—Glomerular hypertrophy
—Alteration in post glomerular blood flow with relative
tubular ischemia.
Added to these could be proteinuria. The abnormal passage
of macromolecules through the glomerular basement membrane
may itself set in train a series of events which leads to end-stage
renal disease. Not only can one argue that proteinuria may
contribute to intrinsic glomerular damage, but also that the
presence of large quantities of protein within the tubules may
have a damaging effect on the interstitium. This is particularly
relevant since attention has recently focused on a long known
but ignored fact that the progression of renal disease correlates
best with interstitial damage and not with glomerulosclerosis
per se [3, 4].
This review will examine the evidence in both humans and
animals which purports to support the "proteinuria hypothe-
sis." It will also address mechanisms whereby increased gb-
merular permselectivity might contribute indirectly to a decline
in renal function.
Proteinuria as a predictor of renal disease
Microalbuminuria is defined as the urinary excretion of
albumin that is persistently above the normal range but that
cannot be detected by conventional urine testing strips. An
accurately timed collection giving an excretion rate of greater
than 20 sg/min is diagnostic. Two hundred micrograms per
minute is generally taken as the upper limit since above this
level it becomes detectable by routine urine testing. Persistent
microalbuininuria in patients with diabetes correlates highly
with the eventual development of overt diabetic nephropathy
[5, 6]. Recently, treatment of microalbuminuric diabetic pa-
tients with an ACE inhibitor has been reported to reduce the
chances of progression to overt nephropathy [7]. In the treat-
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ment group the decline in albuminuria predicted the attenuated
fall in GFR. This observation does not, however, provide proof
that the albumin loss itself is pathogenic, and in the majority of
published studies there is a small, but significant, number of
patients with persistent microalbuminuria who do not progress
to overt nephropathy. Type I diabetic patients with established
renal disease usually have hypertension as well as proteinuria.
Treatment of the raised blood pressure is associated with a
reduction in the rate of decline of GFR and at the same time a
decrease in proteinuria [8]. Whether the latter contributes to the
former remains unknown.
Proteinuria—a cause of progression?
Persistent overt proteinuria is also linked with a worse
prognosis in a number of common glomerulopathies [9, 10].
Frequently the association is strongest with the greater magni-
tude of proteinuria [11]. In an analysis of over 400 non-diabetic
patients with proteinuria, Mallick, Short and Hunt observed
that patients whose proteinuria did not exceed 5 gfday rarely
progressed to renal failure [121. This principle is in agreement
with the observations of Cameron [11], that patients presenting
with nephrotic syndrome had a much worse prognosis than did
those without nephrotic range proteinuria.
In a prospective study Williams, Fass and Bone [13] analyzed
the progression of renal failure in 108 patients with a variety of
diseases. Their results indicated that the underlying renal
pathological changes were important in determining the rate of
deterioration (rate of deterioration was significantly faster for
patients with glomerulonephritis and diabetic nephropathy
compared to polycystic renal disease and chronic pyelonephri-
tis). In addition, for those with linear progression there was a
significant correlation between 24-hour protein excretion and
the rate of deterioration. This latter finding, however, tended
not to be a universal relationship, with the best correlation seen
in patients with proliferative glomerubonephritis and little or no
correlation in the small number of diabetic patients studied.
Similarly in the Manchester study [12], although significant
proteinuria was predictive of poor outcome in the majority of
cases, nevertheless, a number of patients suffered heavy pro-
tein losses for years without showing evidence of progression.
Such observations contradicting a causative role for protein-
uria in progression of disease are partly supported by long-term
follow-up of minimal change nephrotic syndrome [14, 15],
where, despite frequently relapsing disease with nephrotic
range proteinuria there was no deterioration of function even
after 20 years of follow-up. To use this latter evidence as a case
against a role for proteinuria in progression is, perhaps, a little
unfair since these individuals did not have sustained protein
443
444 Williams and Coles: Proteinuria and renal damage
leakage and may therefore not be subjected to the same
conditions as those seen in the earlier quoted studies.
it is, however, important to acknowledge again the findings
from the Liverpool study [13] that the rate of progression is
related to the underlying disease and to note that the more
severe the disease the faster the rate of decline. Thus, people
with severe disease do worst and those with severe disease are
most likely to have severe proteinuria. Hence, the hypothesis
becomes self-fulfilling!
In order to identify an unequivocal relationship between
proteinuria and progression one would need to reduce protein-
uria in isolation. Currently in humans this is not possible.
Animal studies
One must therefore examine the evidence from animal mod-
els which has been put forward to support the hypothesis that
proteinuria causes progression. Much of this was collected in a
previous review by Remuzzi and Bertani [16] and centered on
the correlation between proteinuna and glomerulosclerosis.
Reduced nephron mass
Renal ablation is a model frequently used to study decline in
renal function. In these animals glomeruloscierosis naturally
follows the reduction in renal mass [17]. The initial change that
follows renal ablation is an increase in single nephron GFR in
the remaining glomeruli. This results in a sustained increase in
pressure in these nephrons [181, leading to glomerular injury
[191 and eventual sclerosis. In these animals there is a signifi-
cant correlation between proteinuria and glomeruloscierosis.
Proteinuria develops early in the disease and precedes the
decline in function. Indeed, detailed studies in the Munich-
Wistar rat indicate that the origin of proteinuria following renal
ablation is from glomeruli with minimal structural changes [20],
and thus a change in permselectivity is a reflection of increased
glomerular capillary pressure rather than a result of gross
morphological changes.
In such a model of renal disease a number of manipulations
may protect the animals against progression including a reduc-
tion in protein intake, the administration of angiotensin convert-
ing enzyme inhibitors or calcium antagonists [21, 22]. Further-
more, each of these maneuvers also reduces proteinuria.
Interestingly, however, the remnant kidney model also pro-
vides evidence in opposition to the proteinuria-progression
hypothesis. In the early 80's Kaysen and Kropp [23] while
studying the effect of dietary tryptophan supplementation on
albumin synthesis in the uremic rat noted that, although pro-
gression was unaffected by tryptophan supplementation, pro-
teinuria and albuminuna were greatly ameliorated. Thus, renal
pathology progressed despite reduction of proteinuria. In a
separate study Reyes and colleagues [24] examined the effect of
dietary supplementation with L-arginine on the progression of
renal disease following subtotal nephrectomy. Interestingly,
those animals receiving L-arginine supplementation were pro-
tected from glomerulosclerosis, despite persistent proteinuria at
a level comparable to those animals with progressive disease.
The analbuminemic rat has also been studied in an attempt to
pin point a role for proteinuria in progression. Subtotal nephrec-
tomy was performed on Sprague-Dawley rats [SDR] and an
albuminemic SDR variant [NAR] [25]. Proteinuria in the SDR
group was significantly (3-fold) greater than in the NAR group.
Despite this glomerulosclerosis was greater at 18 weeks post-
nephrectomy in the NAR group. The results of this study
indicate that tubular protein overload per se is not the major
contributing factor to progressive renal disease following sub-
total nephrectomy in this model. It could be argued that the
leakage of macromolecules other than albumin might contribute
to renal damage, but a role for albumin itself is certainly ruled
out.
Finally, in a normotensive rat remnant kidney model devel-
oped in the Wistar-Kyoto strain, Bidenic and coworkers dem-
onstrated that glomerular hyperfiltration and hypertrophy after
5/6th nephrectomy may not lead to a decline in renal function as
long as systemic hypertension does not develop [26]. Interest-
ingly, those animals that remained normotensive had relatively
little evidence of glomerulosclerosis by 16 weeks despite signif-
icant proteinuria.
Overload proteinuria
An alternative approach to the study of proteinuria has been
the induction in animals of hyperproteinemia which results in
"overflow proteinura." The most commonly adopted approach
has been the infusion into a rat of heterologous protein, usually
bovine serum albumin.
Proteinuria usually appears within 24 hours. At its peak 50 to
75% of the urinary protein comprised the heterologous, infused
protein. The remainder was homologous protein, mainly rat
serum albumin. Thus, the infusion of heterologous BSA in-
duced homologous proteinuria. After five days of administra-
tion the BSA infusions were stopped but homologous protein-
uria persisted for the duration of the study [27]. Interestingly, in
the same study the infusion of egg albumin although resulting in
heterologous proteinuria did not cause homologous proteinuria.
These results suggest that the homologous proteinuria induced
by BSA infusion is the result of a toxic effect of the heterolo-
gous protein and not simply a consequence of proteinuria per
se. It may be that the BSA acts as a carrier for a toxic molecule
such as lipid A. The use of homologous protein infusions [28]
tends to confirm the above conclusions. The daily administra-
tion of rat serum albumin for up to eight weeks induced
significant proteinuria. There were minor changes in glomerular
epithelial cell [GEC] function but interestingly foot process
fusion did not occur. When exogenous protein administration
was stopped, proteinuria stopped and GEC appearance re-
turned to normal.
Most recently the effect of protein overload proteinuria on
interstitial nephritis was studied [29]. Again most of the exper-
iments were carried out using bovine serum albumin of unde-
fined purity. Only two animals were given homologous protein
and although they also developed interstitial infiltrates the
numbers are too small to draw meaningful conclusions.
Protein overload proteinuria has also been established by the
induction of hyperalbuminuria in rats following the transplan-
tation of the rat pituitary tumor MtT SAS [30]. The animals
subjected to tumor transplantation developed proteirniria and
glomerulosclerosis. Although this has been put forward as a
model of proteinuria-induced renal disease, the high levels of
growth hormone reached following tumor transplantation result
in significant renal hypertrophy. No data exist on glomerular
hemodynamics in this model, but other studies have highlighted
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a role for growth hormone in the development of glomerulo-
sclerosis [31, 32].
Epithelial cell toxins, rat models of minimal change disease
The acute administration of the aminonucleoside of puromy-
cm [PAN] to rats has been shown to result in the development
of nephrotic syndrome with morphological alterations similar to
those observed in minimal change disease [33]. Repeated ad-
ministration of the molecule results in progressive changes
similar to those seen in focal glomerulosclerosis [34]. In addi-
tion to glomerular changes there is an acute interstitial infiltrate
which is mainly macrophage in content [35]. This is strongly
correlated with the degree of albuminuna in the experimental
animals.
Similar functional and structural changes are often seen
following adriamycin administration [36], although the morpho-
logical changes do not appear as dramatic unless the animals are
also subjected to simultaneous subtotal nephrectomy. This
difference between the two models of epithelial cell toxicity
does in fact allow a separation of glomerulosclerosis from
proteinuria [37] and add further weight to the argument that
progression and proteinuria may well be distinct entities of the
same disease. In a separate study adriamycin was administered
to Nagase analbuminemic rats [NA] to generate a model of
glomerulosclerosis [38]. Interestingly, despite a lack of albu-
min, the analbuminemic rats developed the same degree of
sclerosis as did their Sprague-Dawley counterparts which also
received adriamycin. The authors concluded that albuminuria
was not an aggravating factor in focal glomeruloscierosis.
Aging
Finally, it is well-documented that in certain strains of rat
aging is associated with proteinuria, nephrosclerosis and pro-
gressive renal impairment [39—41].
In the fawn hooded rat proteinuria has been identified as a
marker for the future development of renal impairment [40].
Those animals with the greatest degree of proteinuria exhibited
the most rapid decline in renal function. They were also the
more hypertensive animals, and previous publications have
correlated increased blood pressure with progression in this
strain [42]. Bertani and colleagues [41] examined the aging
kidney in the Sprague-Dawley rat and compared the effects of
different protein diets on the decline of renal function. They
documented that a low protein diet normalized urinary protein
excretion and prevented glomerular morphologic changes. As a
result of this they concluded that proteinuria could contribute to
both glomerulosclerosis and tubulointerstitial damage. Equally
well, however, the mechanism of protection afforded by protein
restriction might be related to the difference in glomerular
filtration rate in the animals on different protein intakes [43].
Early studies by Hostetter and coworkers demonstrated clearly
that increased protein intake was directly related to increased
single nephron GFR and a rise in intraglomerular pressure [18].
Thus the correlation between protein intake and declining renal
function might simply reflect haemodynamic changes within the
glomerulus with its consequent effect on glomerular and inter-
stitial morphology.
The evidence presented to date, at best, represents a corre-
lation between proteinuria and the progression of renal disease.
There is certainly a logic to the argument that mechanisms exist
whereby proteinuria might indirectly contribute to renal dam-
age, but a direct causal relationship with declining renal func-
tion has not been unearthed. It must therefore be concluded
that an apparently meaningful relationship between two param-
eters need not directly indicate causality and may overlook the
fact that the two functions are determined by a third or
unknown mechanism [44].
With this in mind, however, there are a number of ways in
which persistent loss of protein into the urine might contribute
to the morbidity of renal disease.
Does hypoproteinemia (the loss of plasma proteins) result in
secondary events which might influence the glomerular disease?
The nephrotic syndrome is accompanied by significant
changes in plasma lipids [45] which can be reversed by correc-
tion of the hypoproteinemia. The decrease in plasma albumin is
accompanied by a rapid increase in cholesterol and to a lesser
extent triglycerides. Most specifically there is an increase in the
cholesterol content of LDL and VLDL. The pathogenesis of
these lipid abnormalities remains controversial, but appears to
involve both increased lipoprotein production by the liver and
decreased catabolism of particles in the circulation, in particu-
lar a decrease in the number of LDL (apo B) receptors in the
liver. A direct causal relationship between lipid abnormalities
and renal disease is difficult to demonstrate. However, the
majority of patients with an inherited deficiency of the enzyme
lecithin:cholesterol acyl transferase (LCAT) are hyperlipidemic
from an early age and eventually develop renal failure [46].
Similarly, secondary LCAT deficiency is also associated with
glomerulosclerosis.
When considering the possible mechanisms of glomerular
damage, nephrosclerosis has been compared to atherosclerosis
[47—49] and parallel mechanisms identified whereby LDL dep-
osition in the mesangium is analgous to LDL deposition in the
arterial wall. Further, oxidative modification of LDL may
contribute to its pathogenicity [50]. Both arterial smooth muscle
cells and glomerular mesangial cells express on their surface
LDL receptors [51]. Human mesangial cells in culture prolifer-
ate in response to oxidized LDL and release vasoactive ei-
cosanoids [52]. By implication the control of hyperlipidemia in
patients with the nephrotic syndrome might not only result in
the possible control of atherosclerosis, but also contribute to
the prevention of progressive glomerular damage by limiting the
deposition of intraglomerular LDL.
In addition to the changes in plasma lipids, most patients with
nephrotic syndrome develop an increased tendency to throm-
bosis. This may manifest in the systemic venous system and
contribute to intraglomerular thrombosis. Thrombocytosis is
present in up to 50% of adults with nephrotic syndrome [53] and
is accompanied by an increase in platelet aggregabiity [54].
Clinically important alterations in coagulation factors are less
consistent. The most common finding is an elevated fibnnogen
level. Concentrations of other natural pro- and anticoagulants,
however, are much more variable, and studies of fibrinolysis in
nephrotic syndrome have yielded conflicting results [55]. Over-
all the level of circulating factors reflect the level of plasma
albumin, but since both pro- and anticoagulants are frequently
low in hypoproteinemia there is no consistent pattern to the
defects observed.
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Fig. 1. Mechanisms whereby immune damage
to the GBM results in the leakage of
complement components to the epithelial side
of the membrane. This may facilitate the
assembly of the membrane attack complex on
the epithelial cell and disrupt the normal GBM
turnover.
Experimental models of glomerulonephritis with proteinuria
are accompanied by hypercoagulability, glomerular capillary
occlusions by fibrin and the presence of platelet thrombi early in
the course of glomerular damage. Such models of renal disease
frequently respond to anticoagulation and/or antiplatelet ther-
apy. Unfortunately, a consistent response in humans to such
intervention has not been the rule.
Does this exposure of extracapillary regions of the glomerulus
to plasma proteins result in morphological or functional
changes?
Under normal circumstances the size and charge selectivity
of the glomerular capillary barrier limit the type of macromol-
ecule that gains access to the urinary space. The result of
proteinuria is that both visceral and parietal epithelial cells are
exposed to a microenvironment to which they are hitherto
unaccustomed. During development the GBM is produced
jointly by the endothelial cell and the visceral epithelial cell. In
adulthood the major responsibility for the turnover and replace-
ment of this membrane lies almost entirely with the epithelial
cell. It would therefore not be unreasonable to argue that any
inflammatory or immunological process that affects the epithe-
hal cell might disrupt the integrity of the GBM.
One such process might result from the passage of comple-
ment components across the GBM. It has been known for some
time that the epithelial surface of the GBM can activate
complement via the alternative pathway [56]. In an animal
model of membranous nephritis Kerjashki and colleagues have
demonstrated that the terminal components of the complement
cascade (the membrane attack complex; MAC) can be assem-
bled on the basement membrane face of the glomerular epithe-
hal cell [GEC] (personal communication). Cultured human
GEC when exposed to sublytic concentrations of MAC gener-
ate vasoactive eicosanoids [57], synthesize type IV collagen
[58] and neutral metalloproteinases [59]. One could therefore
construct a model whereby the leakage of plasma components
across the GBM might have a pathophysiological effect on the
GEC and disrupt the normal process of GBM turnover (Fig. 1).
It is also well-recognized that forms of glomerular disease
exist which are not accompanied by the deposition of immune
deposits within the glomerulus, such as the ANCA positive
diseases. Nevertheless, in rapidly progressive nephritis there is
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an inflammatory reaction clearly occurring within the urinary
space with the accummulation of macrophages and lympho-
cytes as well as proliferating parietal epithelial cells. One
possible trigger for such a process is the ability of the glomer-
ular epithelial cell to function as an antigen presenting cell and
express processed antigen along with class II MHC molecules
[60]. Thus, the passage of certain antigenic components across
the GBM, their subsequent uptake by epithelial cells, process-
ing and expression with MHC class II molecules may result in
amplification of the immune response and further glomerular
damage.
In addition to the accumulation of proteins in the urinary
space it has been suggested that proteinuria is accompanied by
an increased flux of macromolecules through the glomerular
mesangium. In an experimental model of focal glomeruloscle-
rosis it was shown in the early stages of disease that mesangial
"overload" accompanied proteinuria and preceded structural
glomerular damage [611. No satisfactory explanation for in-
creased mesangial trafficking has been advanced. Interestingly,
however, neither adriamycin induced proteinuria nor Heymann
nephritis are accompanied by the increased trafficking of aggre-
gated IgG observed in puromycin aminonucleoside nephrosis
[62]. Thus mesangial changes are not universally seen in all
animal models with significant proteinuria and are an indepen-
dent feature of certain diseases.
Does the presence of large quantities of plasma proteins in the
tubules contribute to renal damage?
Under normal circumstances those plasma proteins which
traverse the GBM re-enter the circulation during their passage
along the nephron [63]. The absorptive process is highly effi-
cient (> 90%) and takes place mainly in the proximal tubule.
This is a complex process which is charge dependent (cationic
molecules  neutral molecules) and involves endocytosis via
clathrin-coated pits. The endocytotic vesicle fuses with a lyso-
some, the protein is broken down and amino acids or peptide
fragments re-enter the circulation.
Under non-proteinunc conditions the tubule is able to deal
effectively with the filtered load of protein. The result of
increased glomerular permeability will be a substantial rise in
the filtered protein load. Where the increase is of low molecular
weight proteins the capacity of the tubule to deal with these is
usually adequate (although certain small proteins in excess,
such as light chains may be tubulo-toxic). An excess of large
proteins is apparently more problematic. The reserve capacity
of the proximal tubule to deal with large quantities of albumin is
limited [64], although under conditions of excessive proteinuria
tubular lysosomal enzyme activity (cathepsin G and L) in-
creases [65]. This latter finding suggests an increased catabo-
lism of proteins within the tubular cell and supports previous
studies indicating that increased tubulo-absorption of albumin
might occur in the nephrotic syndrome [66].
The next step in the hypothesis is to link the increased tubular
protein load, and increased protein catabolism in tubular cells
to tubular injury and possibly interstitial inflammation. This is
clearly a logical direction in which to extend the hypothesis
since progression of renal disease has been clearly linked to
tubulointerstitial changes [67]. In addition there are a number of
animal studies that purport to link proteinuria and tubulointer-
stitial inflammation [29, 35].
A potential pathway for tubular cell damage is the increased
ammonia production that accompanies overt proteinuria (Fig.
2). In a series of recent studies Rustom and colleagues have
demonstrated that urinary ammonia production is highly corre-
lated with the degree of proteinuria [68]. Using labeled aproti-
nm, they were able to show that in patients with very heavy
proteinuria there is increased tubular metabolism, a lower
uptake and a higher fractional degradation of protein and that
this correlated with the degree of ammonia production.
Previous studies have suggested a role for ammonia in
progressive interstitial nephritis. Renal ammonia production
has a pivotal role in acid-base balance. In impaired renal
function the net ammonia production per surviving nephron is
raised [69, 70] and may even be accompanied by an increase in
cortical ammonia levels [71]. Adult rats undergoing subtotal
nephrectomy were paired to receive either 20% protein substi-
tuted with sodium chloride or 20% protein supplemented with
equimolar sodium bicarbonate to suppress ammonia produc-
tion. The animals fed sodium chloride had higher renal vein
ammonia, increased protein excretion and decreased estimated
renal plasma flow. In addition they had greater histological
evidence of kidney damage including interstitial nephritis.
Thus, those animals supplemented with sodium bicarbonate
had lower ammonia levels, lower proteinuria and a more
favorable outcome [72]. As to the mechanisms of renal damage,
animals with the highest production of ammonia showed wide-
spread peritubular fluorescence for C3 and C5b—9 in the
absence of peritubular IgG. Thus, it is argued that ammonia
through its capacity to activate the third component of comple-
ment [72] can directly result in the triggering of an inflammatory
response in the renal interstitium. This interaction of comple-
ment with ammonia may explain the interstitial deposition of
C5b—9 which is not infrequently seen in the renal interstitium
in immune and non-immune disease [73]. The amidated C3 is
also a potent trigger for reactive oxygen species release from
leukocytes [74]; C5a is a chemoattractant; and sublytic C5b—9
is a potent cell activator [57, 58]. In addition, ammonia itself is
a potent stimulator of cell growth and hypertrophy [75].
Conclusion
In summary, it should be noted that little direct evidence
exists to causally link proteinuria per se with the progression of
renal impairment. Correlations abound, but until the ideal
experiment can be devised where, as a single factor, proteinuria
can be reduced without interfering with any of the other
confounding variables, a direct causative relationship will be
difficult to prove. From the second part of this review, how-
ever, it can be seen that there are many ways in which
protenuria might directly, or indirectly, contribute to renal
damage.
On balance it is improbable that there will be a single "final
common pathway" that leads to end-stage renal failure. More
likely, like most biological systems, it is a multifactorial event in
which proteinuria might play a role. This fact was most ele-
gantly demonstrated by Van Goor and coworkers [76] when
they painstakingly examined the determinants of glomeruloscie-
rosis in the rat after renal ablation. Among the significant
correlations with glomerular damage were urinary protein,
fasting cholesterol, glomerular lipid deposits and macrophage
infiltration.
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On a more practical note, however, the reduction of protein-
uria usually makes patients feel better, and despite the lack of
direct evidence regarding progression the relief of proteinuria
must be a justifiable aim in its own right.
Reprint requests to John D. Williams, M.D., Institute of Nephrology,
University of Wales College of Medicine, Card(ff Royal Infirmary,
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